Live price and daily change for the key stocks inside the Nifty Pharma. This is not the complete list: the full current constituent file is published by NSE Indices.
Constituents change at periodic reviews: confirm against the official NSE index page. Not investment advice.
Nifty Pharma tracks India's pharmaceutical manufacturers — Sun Pharmaceutical, Dr. Reddy's Laboratories, Cipla, Divi's Laboratories, Aurobindo Pharma, Lupin, Torrent Pharmaceuticals, Alkem Laboratories, Abbott India, and Zydus Lifesciences. India is the world's largest supplier of generic medicines, supplying 20% of global generics by volume.
Indian pharma's primary revenue engine is the US generics market where Dr. Reddy's, Sun Pharma, Lupin, and Aurobindo compete on price for FDA-approved generic drug filings. The structural challenge is secular price erosion — as more Indian companies get FDA approval for the same drug, average selling prices fall 10–15% annually. Companies that file First-to-File (FTF) exclusivity applications generate outsized profits on high-value molecules going off-patent.
The US FDA inspects Indian manufacturing plants that supply the US market. An OAI (Official Action Indicated) warning can trigger an Import Alert, blocking that plant's products until remediation is complete. Plants under Import Alert can lose 15–30% of a company's US revenue overnight. The FDA's public Establishment Inspection Report database and 483 observation filings are the best way to track this risk.
The domestic Indian pharma market — driven by chronic therapy (diabetes, cardiac, hypertension), branded generics, and consumer healthcare — is growing at 10–12% annually. Sun Pharma, Cipla, and Torrent have particularly strong domestic chronic portfolios. Unlike the US generics business, domestic formulations are largely insulated from global price erosion and FDA risk.
A US FDA Warning Letter or Import Alert on an Indian manufacturing plant can crash a pharma stock 10–20% intraday. No technical chart can predict it — pure regulatory event risk.
Pharma is considered a defensive sector in India because healthcare demand is relatively inelastic — people need medicines regardless of economic conditions. During broad market corrections driven by global macro factors (US recession fears, FII selling, rising interest rates), Nifty Pharma typically falls less than cyclical sectors. However, pharma-specific risks (FDA actions, price controls via NLEM, patent challenges) can cause individual stock moves of 15–25% that are completely independent of broader market direction.
This is a calculation from history, not a forecast. It takes the Nifty Pharma's own price record (2011 to October 2026, about 16 years) and asks a simple question: if the next five years looked like the typical five-year stretches of the past, where would the index be?
Since 2011 the Nifty Pharma has compounded at about 12.2% a year in price terms (dividends excluded), and about 8.6% a year over the last ten years. Across the 130 overlapping five-year windows in the data, the median five-year result was 8.8% a year. The middle half of outcomes fell between 4.3% and 14.9% a year, the weakest window returned -11.0% a year and the strongest 25.3% a year. About 13% of five-year windows ended lower than they began.
| Date | Lower range 4.3%/yr | Median 8.8%/yr | Upper range 14.9%/yr |
|---|---|---|---|
| Oct 2027 | 27,400 | 28,600 | 30,200 |
| Oct 2028 | 28,600 | 31,100 | 34,800 |
| Oct 2029 | 29,800 | 33,900 | 40,000 |
| Oct 2030 | 31,100 | 36,900 | 45,900 |
| Oct 2031 | 32,400 | 40,100 | 52,800 |
If the next five years matched the median past window, the Nifty Pharma would be around 40,100 by Oct 2031. The lower and upper ranges give 32,400 to 52,800. These are illustrations of past patterns, and the index could finish outside this range, as it has before.
For comparison: repeating the index's full-history pace of 12.2% a year would give about 46,800 by Oct 2031, and a repeat of its weakest past five-year window (-11.0% a year) about 14,700. A single start-to-end figure and the spread of rolling windows can differ a lot, because the first depends on where the record begins and ends, so it is worth looking at both.
We use monthly closing levels from Yahoo Finance and measure the annual growth rate of every five-year window. The lower range applies the 25th percentile of those rates to today's level, the median applies the 50th and the upper range the 75th. Nothing is adjusted for the current market, valuations, earnings or news.
Using the median of past five-year windows, about 36,900 by Oct 2030, with a historical-pattern range of roughly 31,100 to 45,900. That range comes from the index's own history and is not a prediction, and the weakest past five-year window would have given about 16,500 over the same period.
Using the median of past five-year windows, about 40,100 by Oct 2031, with a historical-pattern range of roughly 32,400 to 52,800. That range comes from the index's own history and is not a prediction. About 13% of past five-year windows were negative, so a lower result is part of the historical record too.
निफ्टी फार्मा में सन फार्मा, सिप्ला और डॉ. रेड्डीज़ जैसी दवा कंपनियाँ शामिल हैं। अमेरिकी FDA का भारतीय संयंत्रों पर निरीक्षण (क्लीयरेंस या चेतावनी), अमेरिका में जेनेरिक दवाओं की कीमतें और तिमाही नतीजे इस इंडेक्स को सबसे ज़्यादा प्रभावित करते हैं।
सबसे ज़्यादा US FDA की निरीक्षण रिपोर्ट, जेनेरिक दवाओं की अमेरिकी कीमत से जुड़ी नीति और बड़ी कंपनियों के तिमाही नतीजों से।
Key Nifty Pharma constituents include Sun Pharma, Cipla, Dr. Reddy's Laboratories, Divi's Laboratories, Lupin, Zydus Lifesciences, Aurobindo Pharma, Torrent Pharma. See the official NSE Indices page for the full current list.
Risk Disclaimer: Commodity futures trading involves substantial risk of loss. The data and analysis on MCX Trends are for educational purposes only and do not constitute investment advice. Always consult a SEBI-registered investment advisor.